IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun a phase III trial of its anti-lymphoma antibody IDEC-C2B8 in patients with relapsed low-grade and follicular non-Hodgkin's lymphomas. The company is developing the agent in collaboration with Genentech, Inc.

SAN DIEGO, Calif--IDEC Pharmaceuticals Corporation has begun aphase III trial of its anti-lymphoma antibody IDEC-C2B8 in patientswith relapsed low-grade and follicular non-Hodgkin's lymphomas.The company is developing the agent in collaboration with Genentech,Inc.

Up to 200 patients in this single-arm, single-agent trial willreceive four weekly infusions of IDEC-C2B8.

The antibody binds to the CD20 antigen, which is expressed onthe surface of mature B cells and B-cell tumors, but not on B-cellprecursors or plasma cells. Host defenses are thus recruited tokill both malignant and normal B cells. After treatment, the normalB cells regenerate from stem cells within months,IDEC said.

Articles in this issue
IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma
Dr. Peters Named Head of the Michigan Cancer Foundation
Broad-Spectrum Sunscreens Block UVA and UVB
Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca
Outpatient ABMT at Duke Leads to Savings
Russia Is Taking First Steps to Deliver Its Health-Care System Out of Chaos
Algorithm Optimizes Value of CA125 II Screening for Ovarian Ca
Better Ovarian Cancer Outcome With IP Cisplatin
Counseling Must Go Hand in Hand With Genetic Testing for Breast Cancer
Epirubicin Effective But Toxicity Is Increased
Aggressive 16-Week Multidrug Regimen Improves Breast Cancer Survival
Telomerase Appears to Play a Role in Cancer Cell Immortality
Changes in Health-Care Delivery Could Alter System of Medical Ethics
Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines
NIH Granted Gene Therapy Patent

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
1 expert in this video
1 expert in this video
1 expert in this video
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
2 experts are featured in this series.
2 experts are featured in this series.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Related Content
Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC

Roman Fabbricatore
April 15th 2025
Article

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Tim Cortese
April 15th 2025
Article

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Tim Cortese
April 15th 2025
Article

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity

Viviana Cortlana, MS4;Kennedy Itodo, BS;Yan Leyfman, MD;Jenna Ghazal, BSc;Vraj JigarKumar Rangrej, MBBS;Adhith Theyver;Chandler H. Park, MD, FACP
April 15th 2025
Article

Artificial intelligence may mitigate overdiagnosis and unnecessary treatments in cancer cancer care by integrating with precision medicine.